anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The tattooing was performed at 24-48 hours before the surgery. When the lesion was identified by endoscopy, 2-3 ml of the patient's peripheral venous blood without heparin preparation were injected submucosally at the distal side and proximal side of the lesion using a conventional endoscopic needle without submucosal injection of normal saline.
Pharmaceutical prepn. comprises petroleum contg. 15-20 g/l dissolved Oleander leaves of Nerium oleander. A 1 l clear glass jar is filled with conventional petroleum (e.g. a crude oil fraction in the boiling range 150-280 deg. C), 15-20 g fresh oleander leaves from fully grown Nerium oleander are added and the jar is sealed and allowed to stand in a well lit place for 10 days with periodical shaking. Any undissolved solid residue is then filtered off to leave a light green coloured preparation which can be used as is or e.g. emulsified with water and an emulsifying agent to give a salve type prod. USE/ADVANTAGE - The prepn. is produced from natural prods. and is relatively cheap to produce. It is useful for treatment of diseases of the motor functions e.g. rheumatism, arthritis, lumbago, gout, back ailments, sporting injuries, etc. The prepn. is rubbed into the affected area and is absorbed well to relieve pain and muscle tension and to restore mobility.
BACKGROUND: World Health Organization human papillomavirus (HPV) vaccination recommendations include a single- or two-dose schedule in individuals 9-20 years old and advice for generating data on single-dose efficacy or immunobridging. The ongoing Phase 3 trial of Innovax's bivalent (types 16 and 18) HPV vaccine (Cecolin®) assesses in low- and middle-income countries alternative dosing schedules and generates data following one dose in girls 9-14 years old. Interim data for the 6-month dosing groups are presented.
METHODS: In Bangladesh and Ghana, 1,025 girls were randomized to receive either two doses of Cecolin at 6-, 12-, or 24-month intervals; one dose of Gardasil® followed by one dose of Cecolin at month 24; or two doses of Gardasil 6 months apart (referent). Serology was measured by enzyme-linked immunosorbent assay (ELISA) and, in a subset, by neutralization assays. Primary objectives include immunological non-inferiority of the Cecolin schedules to referent one month after the second dose. Safety endpoints include reactogenicity and unsolicited adverse events for 7 and 30 days post-vaccination, respectively, as well as serious adverse events throughout the study.
RESULTS: Interim analyses included data from the two groups on a 0, 6-month schedule with 205 participants per group. One month after Dose 2, 100% of participants were seropositive by ELISA and had seroconverted for both antigens. Non-inferiority of Cecolin to Gardasil was demonstrated. Six months following one dose, over 96% of participants were seropositive by ELISA for both HPV antigens, with a trend for higher geometric mean concentration following Cecolin administration. Reactogenicity and safety were comparable between both vaccines.
CONCLUSIONS: Cecolin in a 0, 6-month schedule elicits robust immunogenicity. Non-inferiority to Gardasil was demonstrated one month after a 0, 6-month schedule. Immunogenicity following one dose was comparable to Gardasil up to six months. Both vaccines were safe and well tolerated (ClinicalTrials.gov No. 04508309).
Participants have 3 Floatation sessions that last up to 90 minutes. Each spaced about a week apart.
The invention discloses a hairdressing method of ecological distillation bath for health preserving, health caring and skin caring. The invention also relates to a device designed especially for the method. The hairdressing method is characterized in that steam with health-care and/or hairdressing components is mixed with oxygen-supplier evenly and then led to a closed space. The body can be in the space and distilling for 30 to 90 minutes. 2 to 5 minutes later after distillation, effective microbiota is sprayed into the closed space and forces on the body by respiratory tract; or the microbiota is put into water and forces on the skin surface of the body in bath type. The device for implementing the hairdressing method, comprises a distillation bin and a steam producer used for providing steam for the distillation bin, as well as an atomizing turbulent device which is used for providing oxygen supplier and mixing the oxygen supplier and the steam generated by the steam producer; the steam producer is arranged on the outside of the distillation bin and communicated with a pipeline, while the atomizing turbulent device is arranged on the path of the pipeline.
West Nile Virus (WNV) infection is a clinical picture that is transmitted from wild birds, its natural host, to humans through mosquitoes and generally shows an asymptomatic course. Influenza-like WNV fever is frequently seen in symptomatic individuals, and a neuroinvasive course is more rarely observed. Neuroinvasive WNV has a broad-spectrum profile of neurological signs and symptoms. WNV meningitis is one of the most common neuroinvasive forms of WNV, and it does not differ clinically and radiologically from other viral meningitis. Secondary headaches, which can mimic primary headaches, are an infectious factor that should be kept in mind in the etiology, especially in cases presenting in the summer months. In this study, a case of WNV meningitis presenting with a headache of migrainous character is presented.
Many studies have already proved the deleterious effects of LPS on HIV and hepatic diseases evolution. There has never been a concerted effort to prevent the progression of liver disease in these patients. To date, the only treatment is initiation of antiretroviral therapy. Rifaximin could be an easy and well tolerated way to improve the outcome of liver disease in HIV-infected patients. We hypothesize that it could help to slow down the progression of liver disease at any stage in these patients. This is a pilot study. A total of twenty patients placed on rifaximin by their physician for a mild hepatic encephalopathy will be monitored over a period of one year. The evaluation of the fibrosis will be done through transient elastography every 3 months. Bacterial translocation will be evaluated through the dosing of soluble CD14. The safety of the prolonged use of rifaximin in patients will also be assessed.
Among the cognitive disorders due to stroke, attention impairments are frequent and pervading deficits with a variable incidence ranging from 46% to 92% for attention deficits. Stroke patients may have difficulties to focus, pay attention or attend to more than one stimulus at a time. These deficits are insufficiently addressed in the current standard of care. The proposed study is a three-arm (N=45 per group), double-blind, randomized, and actively controlled study. This study uses immersive virtual reality (VR) based training protocols to address attention and executive dysfunctions in patients with stroke. For each cognitive domain, the solution proposes specific gamified activities, with different levels of difficulty, titrated to the patient's level of impairment, assessed by embedded short assessments. The investigators hypothesize that a daily training using VR-based gamified neuropsychological activities, in addition to standard of care, will decrease attention and executive deficits as much as time-matched daily extra neuropsychological sessions of standard of care. The investigators hypothesize too that delivering such daily extra session of VR-based gamified neuropsychological activities in addition to the standard of care will decrease more attention deficits than the actual regular standard of care dose. The primary outcome will be the change in attentional abilities, measured by standardized tests of attention, before and after 20 sessions of VR-based training for the experimental group and 20 additional neuropsychological are sessions for the dose-match control group. The secondary outcomes will include changes in spatial cognition, attention in activities of daily life, executive functions, influence of the lesions' etiology, impression of our rehabilitation program as a credible treatment, among others.
The recruitment process will commence with referrals from local community organizations. Eligible individuals will be provided with detailed information about the study, and informed consent will be obtained from those willing to participate. After the confirmation of participant recruitment, a randomization process will be implemented to ensure the equitable distribution of participants between the intervention and waitlist control groups. An independent researcher will generate computer-generated random codes for group assignment, and these codes will be securely sealed in opaque envelopes. The envelopes will be sequentially numbered, and the randomization process will remain blinded throughout to prevent bias. Participants will be notified via email or text for the details of the condition they are assigned, and their willingness to engage in both the intervention and data collection will be confirmed.
The present invention relates to a kind of sunscreen composition, including：A. aqueous phase；B. at least one cosmetically acceptable oily oil phase is included；C. at least one sunscreen actives agent；With the emulsifier system of gross weights of the d. based on the composition by weight up to about 4.25%, the emulsifier system includes：I. by weight about 0.2% to 0.3% at least one ionic surface active agent；Ii. by weight about 1% to 3% nonionic surfactants of at least one HLB greater than or equal to about 14；With iii. by weight about 1% to 3% nonionic surfactants of at least one HLB less than or equal to about 10；And wherein, the composition is the oil in water emulsion containing the oil droplet that average grain diameter is about 100nm to 150nm, is non-alcoholic and is revealed as when on the skin for be applied to end user translucent to transparent.
FIELD: medicine. SUBSTANCE: the innovation is characterized by the fact that depilatory preparation contains proteolytic enzymes dissolved in microemulsions containing lecithin, aliphatic hydrocarbon, aliphatic alcohol and buffer solution at pH=7-9. Moreover, this value corresponds to pH range being near an optimum pH value of catalytic activity of proteolytic enzymes used for durable enzymatic depilation. Application of such preparations is adequate for all skin types (greasy - nonsusceptible and dry - sensitive). The present innovation enables to use microemulsions as a medium to simplify penetration of enzymatic activity into skin epithelial cells. EFFECT: more durable depilation against that conducted with the help of other depilatory techniques. 7 cl
This is a randomized (study drug assigned by chance), double-blind (neither physician, patient nor the sponsor knows the assigned treatment), placebo-controlled, single and multiple (14 days) ascending dose, parallel group study in 3 study centers (United States, Germany and South Korea). Five cohorts (groups) of patients with Type 2 diabetes mellitus (T2DM) will be studied. One dose level will be evaluated in each cohort. Sixteen (16) patients will be randomly assigned to receive JNJ-28431754 and four (4) patients to receive matching placebo within each cohort. The planned doses are 30, 100, 300 and 600 mg per day. Twice-daily dosing may also be evaluated in one or more of the cohorts. An additional cohort of Asian patients will also be evaluated at a dose level, which was previously tested in a prior cohort and considered to be well tolerated. Blood and urine samples will be collected from patients during the study for pharmacokinetic and pharmacodynamic assessments. The safety and tolerability of JNJ-28431754 will be monitored throughout the study.
The present invention relates to a device and a method for manufacturing ozonated oil using ozonated water. The device comprises a reaction tank containing water and oil existing in layers separated from each other and an ozone generator for supplying ozone to the water in the reaction tank in order to continuously ozonize the water in the reaction tank. The water in the reaction tank is sucked into a first circulation pump and supplied to a first static mixer. The first static mixer is to maximize a gas-liquid contact area between water and ozone, promotes ozonation of the water by passing the ozone received from the ozone generator while mixing the ozone with the water supplied from the first circulation pump, and then re-injects the ozone into the reaction tank to generate and control the water in the reaction tank to high-concentration ozonated water. The process of ozonizing the water in the reaction tank is repeated until the ozonated oil manufacturing is complete. A second circulation pump sucks the oil and ozonated water from the reaction tank and supplies the oil and ozonated water to a second static mixer. The second static mixer promotes the ozonation reaction between the oil and the ozonated water by passing the oil and ozonated water supplied from the second circulation pump while mixing the oil and ozonated water and re-injects the ozonized oil and ozonated water that have progressed due to the accelerated ozonation reaction into the reaction tank. The process of ozonizing the oil is also repeated until the desired final ozonated oil is obtained. Accordingly, it is possible to dramatically shorten the ozonation reaction time of oil.
To fight against increasing rate of bacterial resistance to antibiotics, several studies have demonstrated efficacy of short antibiotic course in e.g. acute streptococcal tonsillitis, community acquired pneumonia, and urinary tract infection. Erysipelas is an acute dermo-hypodermal infection due to streptococcus. To date no resistance of theses bacteria to amoxicillin was described. The diagnosis of erysipelas is clinical. Thus, short course of antibiotic is a good regimen to test in erysipelas treatment. To date there is no controlled trial concerning efficacy of oral amoxicillin in erysipelas treatment. Expected advantages of the demonstration of the non inferiority of a short and oral amoxicillin treatment in erysipelas are: reduction of antibiotic selective pressure, cost, adverse events caused by infusion and hospitalisation.
The dismal prognosis for glioblastoma multiform (GBM) patients is primarily attributed to the highly invasive tumor residual that remained after surgical intervention. The development of precise intraoperative imaging and postoperative residual removal techniques will facilitate the gross total elimination of GBM. Here, a self-disassembling porphyrin lipoprotein-coated calcium peroxide nanoparticles (PLCNP) is developed to target GBM via macropinocytosis, allowing for fluorescence-guided surgery of GBM and improving photodynamic treatment (PDT) of GBM residual by alleviating hypoxia. By reducing self-quenching and enhancing lysosome escape efficiency, the incorporation of calcium peroxide (CaO2) cores in PLCNP amplifies the fluorescence intensity of porphyrin-lipid. Furthermore, the CaO2 core has diminished tumor hypoxia and improves the PDT efficacy of PLCNP, enabling low-dose PDT and reversing tumor progression induced by hypoxia aggravation following PDT. Taken together, this self-disassembling and oxygen-generating porphyrin-lipoprotein nanoparticle may serve as a promising all-in-one nanotheranostic platform for guiding precise GBM excision and empowering post-operative PDT, providing a clinically applicable strategy to combat GBM in a safe and effective manner.
Depression, cognitive impairment and disability often coexist in older adults and contribute to medical and psychiatric morbidity and mortality. We developed and propose to test the efficacy of a new psychosocial intervention, Problem Adaptation Therapy (PATH), for patients with major depression, cognitive impairment (up to the level of mild to moderate dementia) and disability. The proposed R01 study meets a critical need of this population, i.e. a treatment alternative for patients in whom antidepressants may have limited efficacy and for whom psychosocial interventions are underdeveloped and understudied.

The principal innovation of PATH is its personalized approach focusing on the patient's ecosystem (i.e. the patient, the caregiver, and the home-environment) and targeting behavioral problems related to both depression and disability. PATH is delivered at the patients' home, teaches the patient-caregiver dyad problem-solving skills, and incorporates environmental adaptations (including notes, signs, reminders, calendars, voice alarms) to improve the patient's functioning.
Risk Summary

Based on its mechanism of action, Beleodaq can cause teratogenicity and/or embryo-fetal lethality because it is genotoxic and targets actively dividing cells [see Clinical Pharmacology (12.1) and Nonclinical Toxicology (13.1)]. There are no available data on Beleodaq use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. No animal reproduction studies were conducted with Beleodaq. Advise pregnant women of the potential risk to a fetus. 

The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
The evaluation for feasibility of surgery takes place 5-6 weeks after CCRT. Any subject whose tumor status is resectable at evaluation but declines surgical proposal will be eligible to be enrolled in the following study phase.
<P>PROBLEM TO BE SOLVED: To provide an antibody effective for the treatment and/or prevention of infection of Brucella.  <P>SOLUTION: This antibody against the host cell side receptor of Brucella spp. is provided. The host cell side receptor of the Brucella spp. is a protein belonging to a heat shock protein Hsp70 family. The protein belonging to the heat shock protein Hsp70 family is a heat shock cognate protein 70 (Hsc70). The preventing and/or treating agent of the Brucella spp. infection used for domestic animals, pet animals or humans by using the above antibody is also provided.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Sepsis is a multi-organ dysfunction characterized by an unregulated host response to infection. It is associated with high morbidity, rapid disease progression, and high mortality. Current therapies mainly focus on symptomatic treatment, such as blood volume supplementation and antibiotic use, but their effectiveness is limited. Th17/Treg balance, based on its inflammatory property, plays a crucial role in determining the direction of the inflammatory response and the regression of organ damage in sepsis patients. This review provides a summary of the changes in T-helper (Th) 17 cell and regulatory T (Treg) cell differentiation and function during sepsis, the heterogeneity of Th17/Treg balance in the inflammatory response, and the relationship between Th17/Treg balance and organ damage. Th17/Treg balance exerts significant control over the bloom and wanes in host inflammatory response throughout sepsis.
PURPOSE:A composition for the oral cavity, obtained by incorporating methyl p- hydroxybenzoate and/or ethyl p-hydroxybenzoate which are preservatives with PEG together, capable of increasing the solubility and preserving ability, having good feeling of use, and usable for tooth pastes, etc. CONSTITUTION:A composition for the oral cavity obtained by incorporating methyl p-hydroxybenzoate and/or ethyl p-hydroxybenzoate which are preservatives with PEG together. The alkyl p-hydroxybenzoates suitable to a preservative for dentifrice have a disadvantage of slight solubility in water. The combination of the methyl p-hydroxybenzoate and/or ethyl p-hydroxybenzoate selected as the above-mentioned esters and PEG has been found to increase the solubility and enhance the preserving ability. Particularly preferred PEG has 200- 400 average molecular weight, and the preserving ability is remarkably higher than that of the conventional propylene glycol and sorbitol, etc. incorporated with improved feeling of use.
Circulating tumor cells (CTCs) are precursors of distant metastasis in a subset of cancer patients. A better understanding of CTCs heterogeneity and how these CTCs survive during hematogenous dissemination could lay the foundation for therapeutic prevention of cancer metastasis. It remains elusive how CTCs evade immune surveillance and elimination by immune cells. In this study, we unequivocally identified a subpopulation of CTCs shielded with extracellular vesicle (EVs)-derived CD45 (termed as CD45+ CTCs) that resisted T cell attack. A higher percentage of CD45+ CTCs was found to be closely correlated with higher incidence of metastasis and worse prognosis in cancer patients. Moreover, CD45+ tumor cells orchestrated an immunosuppressive milieu and CD45+ CTCs exhibited remarkably stronger metastatic potential than CD45- CTCs in vivo. Mechanistically, CD45 expressing on tumor surfaces was shown to form intercellular CD45-CD45 homophilic interactions with CD45 on T cells, thereby preventing CD45 exclusion from TCR-pMHC synapse and leading to diminished TCR signaling transduction and suppressed immune response. Together, these results pointed to an underappreciated capability of EVs-derived CD45-dressed CTCs in immune evasion and metastasis, providing a rationale for targeting EVs-derived CD45 internalization by CTCs to prevent cancer metastasis.
This was a randomized, controlled, double-blind clinical trial investigating the short term clinical efficacy of a dentifrice containing Eugenia uniflora L. ripe fruit extract in preventing gingivitis in children. The study consisted of a sample of 50 male and female subjects between the ages of 10 and 12 years old, who had clinical signs of gingivitis. The subjects were randomly assigned to one of two groups. The intervention group comprised 25 subjects who used the dentifrice with E. uniflora L. ripe fruit hydroalcoholic extract, three times per day, for seven consecutive days. The control group comprised 25 subjects who used the control dentifrice (fluoride, 1500 ppm and triclosan, 0.3%) for seven consecutive days.

The sample size was estimated using Fleming's single-stage procedure for phase II trials. With regard to the primary outcome, a response proportion of at least 50% was defined as being clinically significant. The type I error was set as 0.05, and the type II error was set at 0.1. Based on these values, a sample size of 20 individuals per trial arm would provide 90% power (1-β) to detect any clinically relevant treatment difference of 50% or greater compared to baseline. Taking into consideration an attrition rate of approximately 20%, the final sample size per trial arm comprised 25 individuals.

Clinical examinations were performed at baseline and after seven days of dentifrice use. The examination was performed by a single examiner who was adequately calibrated with a Kappa statistic of 0.8, which is considered to be satisfactory agreement according to Landis \& Koch. The examination data were recorded in a specific clinical chart. The diagnosis of gingivitis (primary outcome) was assessed using the Gingival Bleeding Index (GBI) proposed by Ainamo and Bay. The accumulation of biofilm (secondary outcome) was assessed with the Simplified Oral Hygiene Index (OHI-S) described by Greene and Vermilion. Prior to the study, all of the subjects were instructed on correct tooth brushing techniques and received a kit that contained a toothbrush and one of the dentifrices (without the identification of its contents). The dentifrices were also masked with regard to flavor and color so that they could not be identified. In addition, the examiner had no knowledge of the subject allocation. Thus, the study was double-blind.

The sample included only subjects who had not used an antimicrobial in the last two months, including topical fluoride.